GLS and malignant colon neoplasm: Herein, we have approached this by analyzing transcriptomic and metabolomic responses elicited in colon cancer cells that persist after exposure either to the CDK4/6i Palbociclib or the glutaminase inhibitor Telaglenastat (CB-839), or their combination, in vitro and in vivo.